Navigation Links
Biospace Lab Collaborates With ImaBio Group to Develop a Unique X-Ray Tomographic Module for its Preclinical Imaging System

PARIS, December 6, 2011 /PRNewswire/ --

Biospace Lab and the ImaBio Group (IPHC, Strasbourg) are pleased to announce they are collaborating on the development of a new X-ray tomographic imaging module for use with the Biospace Lab PhotonIMAGER™ OPTIMA system, a fully modular and versatile preclinical optical imager developed for real-time in vivo luminescence or fluorescence studies. The new add-in module will be faster than current Micro CT systems and will provide more information on organs and tissues, while delivering a low radiation dose compatible with longtitudinal animal studies. Co-registration of anatomical data with optical data will help increase the reliability and accuracy of the functional data acquired.

"As multimodality becomes more and more important for the development of optical imaging systems, such multi-disciplinary collaborations are essential to better serve the needs of Life Science research. ImaBio's expertise in the development of multi-modal imaging systems offers a great opportunity for us to jointly develop an additional add-in module for the PhotonIMAGER™ OPTIMA system that is totally unique in its technology and performance," says Olivier Merle, CEO of Biospace Lab.

"This collaboration reflects our desire to make bio-medical imaging a performing technology. We are very pleased to work together with Biospace Lab, whose PhotonIMAGER™ system plays an important role in our research projects as well as improving the visibility of our laboratory imaging platform today," says David Brasse, head of the ImaBio group.

About Biospace Lab

Based in Paris, France, Biospace Lab S. A. designs and develops a unique range of scientific instruments dedicated to real-time preclinical imaging for in vivo and ex vivo applications in small animals. Biospace Lab has developed a comprehensive portfolio of innovative solutions for ex vivo, in vivo and now in actio molecular imaging; which are used by almost every major pharmaceutical company and many prestigious academic research institutes worldwide.

About ImaBio

The ImaBio group, created in 2001, uses the different skills developed for High Energy Physics experiments at the Institut Pluridisciplinaire Hubert Curien (IPHC, UMR 7178), (University of Strasbourg, and the CNRS, the French National Scientific Research Center). The group activity splits into two domains, the development of per-operating tools to assist surgeon (in breast cancer treatment for example), and the design of A Multi Modality Imaging System for Small Animal (AMISSA) (µCT, µSPECT, µPET).

SOURCE Biospace Lab
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioSpace Showcases Southern Californias Growing Life Science Region
2. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
3. Raydiance Collaborates With Rutgers University and Nations Largest Tissue Bank to Develop Innovative Tissue Processing Approaches
4. GlaxoSmithKline Collaborates with National Cancer Institute to Make Large Body of Cancer Cell Genomic Data Available to All Cancer Researchers
5. SIRO Clinpharm Collaborates with Mediscis, Broadens Early Phase Drug Development Expertise
6. Brainlab Collaborates With Toshiba Medical Systems on Integrated Surgical Suite
7. Cepheid Collaborates With Pharmaceutical Leader on Chronic Myelogenous Leukemia
8. CoreLab Partners Collaborates at Worldwide Industry Conferences
9. PharmaNet Collaborates With the Cancer Immunotherapy Trials Network
10. MDA Collaborates with AVI BioPharma on First Phase 2 Placebo-Controlled Clinical Trial of Exon-51 Skipping Drug as Potential Therapy for Duchenne Muscular Dystrophy
11. Baxter and The Alzheimers Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients With Alzheimers Disease
Post Your Comments:
(Date:11/30/2015)... SAN DIEGO , Nov. 30, 2015 ... ARNA ) today announced that the U.S. Food ... New Drug Application (NDA) for an extended release formulation ... offer patients a chronic weight management treatment in a ... currently approved as an adjunct to a reduced-calorie diet ...
(Date:11/30/2015)... MOUNTLAKE TERRACE, Wash. and ST. ... Cross and Express Scripts (NASDAQ: ESRX ) today ... benefit agreement. The partnership, which began in 1999, will ... --> --> After evaluating pharmacy ... process, Premera concluded that Express Scripts continues to offer ...
(Date:11/30/2015)... N.H. , Nov. 30, 2015 ... that it will feature its latest solutions for ... early identification of cancer at the Radiological Society ... Chicago from November 29 ... recent product advances including iReveal®, an automated breast ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... 1Heart Caregiver ... of the Federation of Philippine American Chambers of Commerce held from November 6-8, ... , 1Heart Caregiver Services, as an active delegate from the Philippine American Chamber ...
(Date:11/30/2015)... , ... November 30, 2015 , ... Until now, the ... set forth in the MOMS (Management of Myelomeningocele Study) trial. One of these exclusion ... and Prevention), a BMI of 18.5 to 24.9 is considered normal, 25 - 29.9 ...
(Date:11/30/2015)... ... ... According to research by the National Association of Dental ... certified or obtain continuing education. To increase awareness of the lack of standards ... inform dentists that the technicians they trust could lack the skills and knowledge ...
(Date:11/30/2015)... Fla. (PRWEB) , ... November 30, 2015 , ... MOSI ... Land, and Sea along with Back to the Jurassic to their collection of interactive ... INDE has created dynamic worlds that will allow guests to get closer than ever ...
(Date:11/30/2015)... ... November 30, 2015 , ... In ... Halloween festivities, the Word of Life Christian Church of Flint, MI, hosted a ... a giant 1.25 ton pile of candy dubbed “Candy Mountain”. , A Forever ...
Breaking Medicine News(10 mins):